No exclusivity for Ranbaxy’s FDA approved drugs - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

No exclusivity for Ranbaxy’s FDA approved drugs

Mar 22, 2000

The US Food and Drug Administration (FDA) has given Ranbaxy’s wholly owned US subsidiary, Ranbaxy Pharmaceuticals Inc. permission to market pentazocine plus naloxone tablets in the USA. These are used for relieving acute pain post–operative surgeries. Ranbaxy is among the top Indian pharmaceutical companies ranks second in terms of domestic sales. It has interests in anti–infectives, respiratory and cardiovascular. It possesses 12 brands among the top 250 brands in the country and in terms of its therapeutic dosage offerings covers around 77% of the market.

With almost $32 bn worth of drugs going off patent (more than 5 times the Indian market) over the next four year’s in the USA, top Indian pharma companies are focusing on the US generic market to drive topline growth. Bottomline performance however, is critically dependent on the time to the market. This is so since within the first two years prices of generic drugs drop almost 80%. Hence it is the first two entrants which make money on the introduction of a new drug in the generic market.

An approval for the generic product has already been granted to a US based company and hence Ranbaxy would not enjoy the 180–day period of exclusivity that the first company getting generic approval is entitled to. So, how lucrative the introduction of these drugs will prove for Ranbaxy remains to be seen.


Equitymaster requests your view! Post a comment on "No exclusivity for Ranbaxy’s FDA approved drugs". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

I Believe These Stocks Will Deliver the Most Outsized Returns in 2021 and Beyond (Profit Hunter)

Sep 23, 2020

Rules of the racetrack can help you bag the biggest gainers of the coming decade.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS